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Objective: Adults with Prader–Willi syndrome (PWS) are at increased risk of developing 
age-associated diseases early in life and, like in premature aging syndromes, aging might be 
accelerated. We investigated leukocyte telomere length (LTL), a marker of biological age, in 
young adults with PWS and compared LTL to healthy young adults of similar age. As all young 
adults with PWS were treated with growth hormone (GH), we also compared LTL in PWS 
subjects to GH-treated young adults born short for gestational age (SGA).
Design: Cross-sectional study in age-matched young adults; 47 with PWS, 135 healthy, and 75 
born SGA.
Measurements: LTL measured by quantitative polymerase chain reaction, expressed as 
telomere/single copy gene ratio.
Results: Median (interquartile range) LTL was 2.6 (2.4–2.8) at a median (interquartile range) 
age of 19.2 (17.7–21.3) years in PWS, 3.1 (2.9–3.5) in healthy young adults and 3.1 (2.8–3.4) in 
the SGA group. Median LTL in PWS was significantly lower compared to both control groups 
(P < .01). In PWS, a lower LTL tended to be associated with a lower total IQ (r = 0.35, P = .08). 
There was no association between LTL and duration of GH treatment, cumulative GH dose, or 
several risk factors for type 2 diabetes mellitus or cardiovascular disease.
Conclusions: Young adults with PWS have significantly shorter median LTL compared to age-
matched healthy young adults and GH-treated young adults born SGA. The shorter telomeres 
might play a role in the premature aging in PWS, independent of GH. Longitudinal research 
is needed to determine the influence of LTL on aging in PWS. (J Clin Endocrinol Metab 105: 
2053–2059, 2020)
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Prader–Willi syndrome (PWS) is a rare disorder re-sulting in a variable phenotype with muscular hypo-
tonia and failure to thrive during infancy and short 
stature, mental retardation, hyperphagia, and obesity 
in childhood and adulthood (1,2). PWS is caused by 
a lack of expression of the PWS region (q11–q13) on 
the paternally derived chromosome 15, mostly caused 
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in USA
© Endocrine Society 2019.
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), 
which permits non-commercial re-use, distribution, and reproduction in any medium, 
provided the original work is properly cited. For commercial re-use, please contact 
journals.permissions@oup.com
Received 10 September 2019. Accepted 24 January 2020.
First Published Online 5 November 2019.











 user on 17 July 2020
2054  Donze et al  Telomere Length in Prader–Willi Syndrome J Clin Endocrinol Metab, June 2020, 105(6):2053–2059
by a paternal deletion or maternal uniparental disomy 
(mUPD) and in some cases by an imprinting center de-
fect (ICD) or paternal chromosomal translocation (1,3).
Growth hormone (GH) is an approved treatment for 
children with PWS improving body composition, linear 
growth, physical strength, cognition, and adaptive func-
tioning (4–9). Studies have shown that GH treatment 
also benefits adults with PWS, with a sustained improve-
ment in body composition when GH is continued after 
attainment of adult height (10,11). However, up to now 
GH treatment is not registered for adults with PWS. 
Studies in adults with PWS who were not treated with 
GH describe an increased risk of age-associated diseases 
early in life, eg, diabetes mellitus type 2 (T2DM), cardio-
vascular disease (CVD), and cognitive decline (12,13). 
The mortality rate of people with PWS was estimated 
to be 3% per year across all ages, rising to 7% in those 
aged over 30 (14). One explanation for the increased 
mortality rate and risk of age-associated diseases could 
be that, like in premature aging syndromes, the aging 
process is accelerated in PWS (15–18).
Ageing is characterized by a progressive time-
dependent decline of normal tissue and organ function 
and recent studies have shown that telomere shortening 
is involved in this process (19–22). Telomeres are highly 
conserved TTAGGG tandem repeat deoxyribonucleic 
acid (DNA) sequences at the end of each chromosome 
arm. Their main function is to protect the end of the 
chromosomes from inappropriate DNA repair mech-
anisms, preventing the loss of crucial DNA. Telomeres 
shorten during proliferation, and telomere length de-
clines as a function of chronological age. When telo-
mere length becomes critically short, the cell enters 
either senescence (ie, irreversible cessation of division) 
or apoptosis (ie, programmed cell death). The accumu-
lation of senescent cells might be driving the process of 
tissue and organismal aging (21–23).
We hypothesized that accelerated biological aging 
could partly explain the increased mortality rate and in-
creased risk of developing age-associated diseases early 
in life in adults with PWS. Since telomeres are suggested 
to play a role in biological aging and telomere length 
had not yet been studied in people with PWS, we inves-
tigated leukocyte telomere length (LTL) in young adults 
with PWS and compared LTL to healthy young adults of 
similar age. As all young adults who participated in this 
study were treated with GH, we also investigated LTL in 
young adults born short for gestational age (SGA) who 
were also treated with GH. We hypothesized that LTL 
would be shorter in young adults with PWS compared 
to both groups, independent of GH treatment. Finally, 
we assessed whether cognitive functioning and putative 
risk factors for T2DM and CVD correlated with LTL.
Subjects and Methods
Subjects
We included 47 young adults participating in the 
Dutch Young Adult PWS (YAP) study, whose primary 
objective was to evaluate the effects and safety of GH 
treatment in young adults with PWS who were treated 
with GH during childhood. Inclusion criteria were 
(i) genetically confirmed diagnosis of PWS by a posi-
tive methylation test, (ii) at least 2 years of GH treat-
ment during childhood, and (iii) having attained adult 
height, defined as a height velocity less than 0.5 cm per 
6 months and epiphyseal closure as demonstrated by a 
radiograph of the left hand and wrist. Exclusion criteria 
were (i) medication to reduce weight (fat) or (ii) unco-
operative behavior.
We compared LTL in GH-treated young adults with 
PWS to healthy participants from the PROGRAM co-
hort (24) and to young adults born SGA of similar age 
treated with ≥7 years of GH (1 mg/m2/day) because of 
their short stature (25). The healthy participants from 
the PROGRAM cohort were all (i) 17 to 24 years old, 
(ii) born singleton, (iii) caucasian, and (iv) had an un-
complicated neonatal period without severe asphyxia, 
sepsis, or long-term complications of respiratory ven-
tilation and/or oxygen supply. The Medical Ethics 
Committee of the Erasmus University Medical Center 
approved the study protocols. Written informed consent 
was obtained from patients and/or their parents or legal 
representatives.
Anthropometric measurements, body composition, 
and cognitive functioning
All patients with PWS were followed at the Dutch 
PWS Reference Center and treated with biosynthetic GH 
(Pfizer Inc., New York, NY, US) during childhood in a 
dose of 1.0 mg/m2/day (≈0.035 mg/kg/day) and, at the 
time of LTL measurement, in a dose of 0.33 mg/m2/day 
(≈0.012 mg/kg/day). The GH dose was regularly adjusted 
based on calculated body surface area and serum insulin-
like growth factor 1 levels. Standing height was measured 
using a Harpenden Stadiometer and weight on a cali-
brated electric scale (ServoBalance KA-20-150S). Height, 
weight, and body mass index (BMI) were expressed as 
standard deviation score (SDS) using GrowthAnalyser 
4.0 (available at www.growthanalyser.org), adjusting for 
age and sex according to Dutch reference values (26,27).
Systolic and diastolic blood pressure was measured 
using an appropriately sized cuff while sitting and 
expressed as SDS, adjusting for height and sex (28). 
Body composition was assessed by dual energy X-ray 
absorptiometry (DXA; Lunar Prodigy, GE Healthcare, 
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lean body mass (LBM; kg) were assessed. All scans 
were made on the same machine, with daily quality 
assurance. The intra-assay coefficient of variation for 
fat tissue was 0.41 to 0.88% and for LBM, 1.57 to 
4.49% (29). FM was also expressed as percentage of 
total body weight (FM%). LBM was calculated as 
fat-free mass minus bone mineral content. FM% SDS 
was calculated according to age- and sex-matched 
Dutch reference values and LBM SDS according to 
height- and sex-matched Dutch reference values (30). 
The Wechsler Adult Intelligence Scale was used to 
assess total IQ in patients over 16 years of age (31) 
and the Wechsler Intelligence Scale in patients below 
16 years of age (32).
Laboratory measurements
Blood samples were collected after overnight fasting. 
Genomic DNA was isolated from peripheral leukocytes 
using standard procedures. DNA samples were kept 
frozen at –20°C until assayed. All LTL measurements 
were performed in the same laboratory at the University 
of Leicester (Leicester, UK). LTL was measured by the 
quantitative polymerase chain reaction–based tech-
nique as previously described (33–35). Telomere se-
quence copy number (T) and single copy gene number 
in genome 36B4 (S) were measured in separate reac-
tions and calculated relative to a calibrator sample 
(genomic DNA from K562 cell line) included on each 
run. Leukocyte telomere length was subsequently ex-
pressed as T/S ratio. For quality control, all samples 
were checked for concordance between duplicate values 
and samples with >0.2 cycle difference in take-off value 
were excluded and rerun. Samples which amplified out-
side of the linear range of the assay were also excluded 
and rerun. Reproducibility of the assay was tested by 
rerunning 47 samples of the age-matched healthy par-
ticipants and the SGA group together with the PWS 
samples (36). The correlation between the original and 
new LTL results was 0.87, and the mean coefficient of 
variation, 6.4%.
Blood levels of glucose, insulin, total cholesterol, 
low-density lipoprotein cholesterol and high-density 
lipoprotein cholesterol, and triglyceride were determined 
in the Biochemical and Endocrine laboratories of the 
Erasmus Medical Center (Rotterdam, The Netherlands).
Statistical analysis
Statistical analyses were performed with SPSS 24.0 
(SPSS Inc., Chicago, IL, US). LTL was expressed as T/S 
ratio and data as median (interquartile range [IQR]). 
Continuous variables of young adults with PWS, 
healthy young adults, and young adults born SGA were 
compared using Kruskal–Wallis and Mann–Whitney U 
tests, and categorical variables were compared using 
Chi-square tests. Analysis of covariance was used to 
correct for age, gender, gestational age, birth length, and 
birth weight SDS.
In young adults with PWS, gender and genotypic dif-
ferences in clinical characteristics were calculated by 
independent samples t tests in case of a Gaussian dis-
tribution and by Mann–Whitney U tests in case of a 
non-Gaussian distribution. Correlations between LTL 
and anthropometric measurements, body composition, 
cognitive functioning, and metabolic health parameters 
were calculated by Pearson correlation analysis in case 
of a normal distribution and by Spearman correlation 
analysis in case of a non-Gaussian distribution. P values 
less than .05 were considered statistically significant.
Results
Clinical characteristics
Forty-seven young adults with PWS (24 females) 
with a median (IQR) age of 19.2 (17.7–21.3) years 
participated in the current evaluation of LTL (Table 1). 
We compared LTL to 135 age-matched healthy par-
ticipants (71 females; median age 20  years) and to 
75 young adults born SGA (33 females; median age 
20  years) who were treated with GH during child-
hood because of their short stature. The distribution of 
males and females was similar between the 3 groups. 
Gestational age, BMI, and FM% in the PWS group 
were significantly higher and LBM significantly lower 
compared to the healthy participants and the SGA 
group (P  <  .02). Age, birth weight, and birth length 
SDS and adult height were lower in young adults 
with PWS compared to healthy participants (P < .04). 
Compared to the SGA group, birth weight, birth 
length, adult height SDS, and duration of GH treat-
ment were higher in young adults with PWS (P < .02), 
and age was similar (P = .47).
Telomere length in PWS and control groups
Median (IQR) LTL was 2.6 (2.4–2.8) in the PWS 
group (Fig. 1). Forty-four young adults with PWS (94%) 
had an LTL below the 50th percentile of healthy young 
adults and 20 (43%) below the 10th percentile. The 
healthy age-matched young adults and the young adults 
born SGA had a similar median (IQR) LTL, which were 
3.1 (2.9–3.5) and 3.1 (2.8–3.4), respectively (Fig.  1). 
Median LTL was significantly lower in young adults 
with PWS compared to both control groups (P < .01), 
also after correction for age, gender, gestational age, 
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Correlation analyses in PWS
Age was not significantly associated with LTL 
(r = –0.18, P = .22), which could be related to the fact 
that subjects in our study population had approxi-
mately the same age. There was no significant differ-
ence in LTL between males and females; median (IQR) 
LTL was 2.5 (2.3–2.8) in males and 2.7 (2.4–2.8) in 
females with PWS (P = .35). Median (IQR) LTL was 
similar in young adults with a deletion (n = 21) and 
a mUPD/ICD (n = 25): 2.6 (2.4–2.8) in both groups 
(P = .97).
There was no significant association between LTL 
and gestational age, birth weight, birth height, adult 
height, BMI, or FM% (P > .28). A lower LTL tended to 
be associated with a lower LBM SDS and a lower total 
IQ (r = 0.29, P = .06 and r = 0.36, P = .08, respectively), 
showing that LBM SDS and cognitive functioning in 
young adults with PWS tend to be lower in those with 
a shorter LTL. Since GH treatment could potentially 
cause increased replicative stress by inducing catch-up 
growth, we analyzed whether LTL was associated with 
the duration of GH treatment or the cumulative GH 
Table 1. Clinical characteristics of young adults with PWS, healthy young adults, and young adults born 
SGA
PWS Healthy SGA
Men/women (n) 23/24 64/71 42/33
Genetic subtype 
 Deletion/mUPD/ICDa 21/22/3/1 NA NA
Gestational age (weeks) 40.6b (38.9; 41.7) 37.0 (33.0; 40.0) 37.4 (33.0; 40.0)
Birth weight (SDS) –1.2b (–2.1; –0.1) 0.4 (–0.4; 1.0) –2.7 (–3.3; –1.6)
Birth length (SDS) –1.1b (–2.2; –0.2) 0.1 (–0.4; 0.7) –3.1 (–4.5; –2.3) 
Age (yrs) 19.2c (17.7; 21.3) 20.0 (19.0; 22.0) 20.0 (18.0; 21.7) 
Height (SDS) –1.0c,d (–1.8; –0.3) 0.00 (–0.4; 0.7) –1.5 (–2.0; –0.8)
BMI (kg/m2) 25.0b (21.8; 27.5) 21.8 (20.5; 23.4) 20.2 (18.8; 22.1) 
BMI for age (SDS) 1.2b (0.0; 1.8) –0.1 (–0.6; 0.6) –0.9 (–1.4; 0.1) 
Duration of GH treatment (years) 13.0d (11.5; 14.0) NA 9.2 (7.1; 11.0)
Fat percentage (%) 39.8b (36.0; 43.6) 22.4 (14.3; 31.4) 18.9 (11.6; 27.8)
Fat percentage (SDS) 2.2b (1.8; 2.5) 0.6 (–0.1; 1.1) 0.5 (–0.1; 1.1) 
Lean mass (SDS) –1.3c,d (–2.1; –0.5) –0.6 (–1.3; 0.1) –0.7 (–1.6; 0.1)
Telomere length (T/S ratio) 2.6b (2.4; 2.8) 3.1 (2.9; 3.5) 3.1 (2.8; 3.4) 
Data expressed as median (interquartile range). 
Abbreviations: BMI, body mass index; mUPD = maternal uniparental disomy; ICD = imprinting center defect; PWS, Prader–Willi syndrome; SDS, stand-
ard deviation score; SGA, short for gestational age; T/S ratio, telomere/single copy gene ratio.
agenotype unknown.
bP < 0.01 compared to healthy young adults and SGA group.
cP < 0.04 compared to healthy young adults.
dP < 0.02 compared to SGA group.
Figure 1. Leukocyte telomere length for age in 47 GH-treated young adults with PWS and 75 young adults born SGA who were also treated 
with GH. The dotted lines represent the 10th and 50th percentile of the healthy young adults. Forty-four young adults with PWS (94%) have a LTL 
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dose, but we found no significant association between 
either. Table  2 shows metabolic health parameters in 
young adults with PWS. Neither blood pressure SDS 
and serum cholesterol levels, nor Homeostatic Model 
Assessment for Insulin Resistance were associated with 
LTL (P > .21).
Discussion
This cross-sectional study in 47 GH-treated young 
adults with PWS shows that median leukocyte telomere 
length (LTL) is shorter in young adults with PWS com-
pared to age-matched healthy young adults and young 
adults born SGA who were also treated with GH. We 
found no significant association between LTL and the 
duration of GH treatment or the cumulative GH dose. 
This is the first study to show that a shorter LTL might 
play a role in the reported accelerated aging process 
in adults with PWS, independent of GH treatment 
(15–17). Sinnema et al described excess functional im-
pairment, morbidity and mortality, and evidence of pre-
mature aging in 12 adults with PWS above the age of 
50 years (17). Aging is characterized by a progressive 
time-dependent functional decline of tissues and telo-
mere shortening is considered to be involved in this pro-
cess (20,21). Individuals with shorter telomere length 
show increased mortality risk, providing support for an 
association between telomere length and lifespan (37).
Besides the finding that LTL is shorter in young adults 
with PWS, we found a tendency toward an association 
between a shorter LTL and a lower total IQ, which might 
imply a role of LTL in cognitive functioning in PWS. 
A  cross-sectional MRI-study in 20 young adults with 
PWS showed that predicted brain age was, on average, 
8.7 years higher than chronological age (38). Together 
with a brain structure resembling healthy older brains, 
indicative of premature neuronal loss and atrophy, this 
suggests premature brain aging in young adults with 
PWS (38). The same research group found a 2.5-year 
higher predicted brain age than chronological age in 46 
adults with Down syndrome. A higher brain-predicted 
age was significantly associated with lower cognitive 
functioning (39), and shorter telomeres have been as-
sociated with cognitive decline and dementia status in 
patients with Down syndrome (40,41). These studies 
support that people with PWS and Down syndrome 
age prematurely. Our study suggests a possible role of 
shorter LTL in this accelerated aging process in adults 
with PWS. However, longitudinal studies on LTL, cog-
nitive functioning and brain development in a larger co-
hort of children and (older) adults with PWS are needed 
to elucidate the natural course of brain development in 
relation to LTL and cognitive functioning.
There is a strong correlation between telomere length 
in different tissues in humans and in other mammals, 
which shows that telomere length in leukocytes reflects 
systemic telomere length in other tissues (42). Besides 
chronological aging, a wealth of genetic and environ-
mental factors are reported to affect telomere length 
(22). Even though none of the genes in the PWS re-
gion on chromosome 15 are associated with telomere 
homeostasis, several clinical features of people with 
PWS are associated with an increased risk of shorter 
telomeres, including obesity, a reduced level of physical 
activity, and increased psychosocial stress. Furthermore, 
adults with PWS are prone to develop T2DM and CVD 
in early life (12,13), and several studies have shown 
that shortened telomeres are associated with an in-
creased risk of T2DM and CVD (20,22,37). As none 
of the investigated young adults with PWS were diag-
nosed with T2DM and CVD, we investigated the inter-
action between LTL and putative risk factors for T2DM 
and CVD. We found no significant correlation between 
LTL and age, BMI, FM%, blood pressure, serum chol-
esterol levels, and Homeostatic Model Assessment for 
Insulin Resistance. This is in accordance with an earlier 
study demonstrating that the association between LTL 
and CVD is independent of risk factors for CVD (35). 
Probably our study group of young adults with PWS was 
too young to already have T2DM or CVD. Also, with 
the more recent trends of early diagnosis, GH treatment 
from a young age, and the enhanced prevention of po-
tentially impairing health conditions, T2DM and CVD 
might occur later in life. It would be interesting to ana-
lyze the association between (risk factors for) T2DM 
and CVD and LTL at a later age, when age-associated 
diseases become more apparent.
All young adults with PWS who participated in 
the current study were treated with long-term GH 
improving body composition, linear growth, physical 
strength, cognition, and adaptive functioning (4–9). To 
evaluate whether GH treatment would cause increased 
Table 2. Risk factors CVD and T2DM
Risk factor
Systolic blood pressure (SDS) 0.8 (0; 1.6) 
Diastolic blood pressure (SDS) 0.6 (0.3; 1.2)
Total Cholesterol (mmol/L) 4.3 (3.9; 4.8)
HDL (mmol/L) 1.3 (1.1; 1.5)
LDL (mmol/L) 2.8 (2.3; 3.2) 
Triglycerides (mmol/L) 0.8 (0.7; 1.2)
HOMA-IR 1.7 (1.2; 2.9)
Data expressed as median (interquartile range).
Abbreviations: HDL,  high-density lipoprotein cholesterol. HOMA-IR, 
Homeostatic Model Assessment for Insulin Resistance; LDL, low-density 
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replicative stress and shorter LTL, we compared young 
adults with PWS to young adults born SGA who were 
also treated with GH. The fact that LTL in young adults 
with PWS was shorter compared to both groups and 
similar in healthy young adults and GH-treated young 
adults born SGA make adverse effects of long-term GH 
treatment on LTL very unlikely (36). Besides, the lack 
of an association between LTL and the duration of GH 
or the cumulative GH dose in young adults with PWS 
is reassuring with regard to possible negative effects of 
GH on LTL.
One could even argue that GH treatment might 
positively influence LTL by improving body compos-
ition. We know that long-term GH treatment during 
childhood counteracts the clinical course of increasing 
obesity in children with PWS and has substantially 
changed their phenotype (4). Combined with an early 
diagnosis and multidisciplinary support from a very 
young age, GH treatment has resulted in a new gener-
ation of children and young adults with PWS without 
severe obesity. Thus, it could be that if our group of 
young adults had not been treated with GH, they would 
have had a higher BMI and FM%, and their LTL could 
have been even shorter. The limited age range and Dutch 
origin of our PWS cohort is both a strength and a con-
straint of our study, since it eliminates the confounding 
effect of age and nationality, but restricts generalizations 
of the results to other age groups and nationalities. Also, 
we were not able to compare LTL in GH-treated young 
adults with PWS to (young) adults with PWS who were 
not treated with GH and more research is needed on 
LTL across the life course and in people of different 
origin to be able to determine its role in aging for both 
GH-treated and untreated people with PWS.
In contrast to previous studies, we found no signifi-
cant difference in median LTL between males and fe-
males. Females have been reported to have longer LTL, 
which is thought to be due to higher levels of estrogen, 
conferring anti-inflammatory and antioxidant proper-
ties and promoting telomerase expression (22). Since 
serum estrogen levels are generally low in females with 
PWS, this could explain the lack of a difference between 
males and females in our study (43). We also found 
similar LTL in young adults with a deletion and those 
with a mUPD or ICD. A  recent study by Whittington 
et al reported on 26 adults with PWS over the age of 
40 years. In 3 participants (aged 41, 48, and 55), there 
was a significant deterioration in executive functioning 
with possible dementia. All were women, had UPD or 
a disomic region, and had had psychotic episodes (18). 
Psychiatric disorders are reported more commonly in 
people with a mUPD and a higher level of psychosocial 
stress is associated with shorter telomeres (22). Based on 
these studies, a difference in LTL between the deletion 
and mUPD subtypes was expected. However, since the 
study group of Whittington et al is considerably older 
than our group and none of the affected individuals 
were treated with GH, it is difficult to compare results. 
We suggest investigating possible differences in LTL be-
tween genetic subtypes in future studies.
In conclusion, we found a shorter LTL in 47 
GH-treated young adults with PWS compared to un-
treated healthy young adults and young adults born 
SGA who were also treated with GH, which might 
suggest that a shorter LTL is involved in the reported 
accelerated aging process in adults with PWS. More 
research on LTL across the life course is needed to 
be able to determine its exact role in aging in people 
with PWS.
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